CTLA4 and neoplasm: Y1.7LI-rechallenged mice that rejected Y1.7LI upon neoAg SLP vax or anti-CTLA-4 and/or anti-PD-1 initiated on day 7, but not untreated naive mice, showed no detectable tumor upon secondary challenge (Figure S2B).